Credit Agricole’s Intellia Therapeutics NTLA Stock Holding History

Credit Agricole’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-146,484	Closed	-$1.88M	–	1366
2026 Q1	$1.88M	Buy	+146,484	New	+$1.87M	﹤0.01%	905

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Credit Agricole's NTLA Position: Q2 2026 in Review

Credit Agricole sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 146,484 shares — an estimated $1.88M sold.

Credit Agricole first reported a position in NTLA in Q1 2026 and held it in 1 quarter. The position peaked at $1.88M in Q1 2026. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Credit Agricole reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
Credit Agricole sold 146,484 Intellia Therapeutics shares in Q2 2026, an estimated $1.88M.
Credit Agricole first reported a position in Intellia Therapeutics in Q1 2026 and held it in 1 quarter.
Credit Agricole's Intellia Therapeutics position peaked at $1.88M in Q1 2026.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Credit Agricole's 13F filing for Q2 2026, filed 14 Aug 2026.